Loading stock data…
Spero Therapeutics, Inc. (SPRO)
$1.19-0.02 (-1.65%)
Market ClosedLast close Sep 8
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spero Therapeutics, Inc. in the Healthcare sector is trading at $1.19 with a market capitalization of $69M. Wall Street consensus targets $4.00 (1 analysts), implying a +236.1% move over the next 12 months. The stock is currently near its 52-week low of $1.08, remaining 46.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +236.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $258,000↓ | $39.66M↑ | $3.05M↓ | $11.80M↑ | $5.11M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.54M↓ | $31.41M↑ | -$7.33M↓ | -$2.36M↑ | -$14.56M |
| Net Income | -$7.20M↓ | $31.52M↑ | -$7.38M↓ | -$1.70M↑ | -$13.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$69.30M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.50
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.70%
Volume
Today's trading volume
348,124
Recent News
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
CEO Rajavelu discusses $105 million financing and SP001 immunology strategy.
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease. Presi
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan.